titanpharm.com (TTNP) Cash Money per Share

Cash per share for Titan Pharmaceuticals (TTNP) exhibits volatile dynamics, with the 2.09 level serving as a critical mark. Growth is supported by licenses for prolonged drug delivery for Parkinson's disease. Stable demand for addiction treatment minimizes the impact of crises, although an acute capital shortage and challenges with implant commercialization significantly weaken the company's market position.
Analytical breakdowns for Titan Pharmaceuticals

Investors utilize this screening to assess the issuer's internal liquidity and solvency. The metric is calculated by dividing the total volume of cash and cash equivalents by the number of shares outstanding. For Titan Pharmaceuticals (TTNP), this metric determines the resource base for the development of implants for opioid addiction therapy. The trend of cash per share over the period demonstrates the business's actual resilience to market shocks.